Premium
Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists
Author(s) -
Albanese A.,
Colosimo C.
Publication year - 2003
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1034/j.1600-0404.2003.02049.x
Subject(s) - pergolide , ropinirole , dopamine agonist , agonist , bromocriptine , cabergoline , lisuride , pharmacology , partial agonist , pramipexole , dopamine receptor d2 , dopamine , medicine , parkinson's disease , chemistry , receptor , disease , prolactin , hormone
The present paper reviews clinical studies on the use of dihydroergocriptine (DHEC), an ergot derivative with dopamine agonist activity, for the treatment of Parkinson's disease. This compound is a hydrogenated ergot derivative structurally quite similar to bromocriptine, from which it differs because of the hydrogenation in C 9 –C 10 and the lack of bromine in C 2 . DHEC has a potent D2‐like receptor agonist and a partial D1‐like receptor agonist activity; because of this biochemical profile, it has been suggested that DHEC may produce fewer side‐effects and have clinical efficacy equal to that of a classical dopamine agonist. Several open‐label and double‐blind studies indicate that DHEC is an efficacious remedy for parkinsonian signs and symptoms. Further studies are necessary to compare DHEC to new dopamine agonists (pergolide, cabergoline, ropinirole, and pramipexole) which have been more recently marketed.